leading to the conclusion that other neurotransmitter pathways, above and beyond serotoninergic ones, can play a role in emergence of this rare and unique phenomenon.
.
Thus, attention shifted to interaction-based models but only few multivariate investigations have been performed in TRD so far 2 . Using the data pool of the Group for the Study of TreatmentResistant-Depression (GSRD) and a machine learning algorithm we intended to draw new insights and back up previous results featuring a set of 66 clinical and demographical predictors for treatment outcome. Methods: 415 patients recruited between 2011 and 2015 in 11 participating centers showed full availability for all 66 predictors. Treatment response was defined by MADRS-score below 22 and a reduction of 50% or more. A score higher than 21 after at least two antidepressant trials of adequat dosage and length was considered as treatment resistance. After generating importance values for all predictors the prediction algorithm was trained in a sample of 385 patients. Subsequently, prediction was performed in a sample of 30 new patients not featured in the model generation. Results: The accuracy for predicting treatment outcome in TRD was at 0.75 using all 66 predictors. Importance measurement revealed chronicity, i.e. full or partial intraepisodic recovery or chronic MDD, number of depressive episodes, age of first and last lifetime depressive episode, total time of hospitalization, education and occupation status, suicidal risk, marital status and number of children and cigarettes smoked per day as the most useful predictors. Conclusion: Exploiting a machine-learning algorithm, we scored an accuracy of 0.75 for treatment outcome using a sample of 415 patients. Reaching a probability of 83.4% for a correct prediction for treatment resistance and 66.6% for response we exceeded the predictive capabilities of clinicians. Thus, these results strengthen our previous data mining approaches and suggest keeping the focus on interaction-based statistical approaches 
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Abstract Objectives: There is considerable evidence that disturbances in neurotransmitter systems contribute to the pathophysiology of depression. Brain-derived neurotrophic factor (BDNF) is involved in the pathophysiology of depression, and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain. Therefore, tPA might be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. Mirtazapine acts as an antagonist of the adrenergic alpha 1, 2 and serotonin receptors. The present study determined the relationship between the Alu insertion/deletion (I/D) polymorphism on the tPA gene and the clinical outcome of mirtazapine treatment in 422 Korean MDD patients. Methods: 422 patients were enrolled in this study, and symptoms were evaluated by 21-item Hamilton Depression Rating scale. After 1, 2, 4, and 8 weeks of mirtazapine treatment, the association between Alu I/D polymorphism on tPA gene and remission/response outcomes were evaluated. Results: The proportion of I/I homozygote in responders was higher than that in non-responders, whereas the proportion of D/D homozygote in responders was lower than that in nonresponders at 8 weeks of treatment (P=0.032, OR=1.57). The percent decline of HAMD-21 score in I allele carriers was larger than that of D allele homozygotes at 2 and 8 weeks after mirtazapine treatment (P=0.035 and 0.007, respectively). I allele carriers were also significantly associated with remission at 8 weeks of treatment (P=0.047, OR=2.2). Conclusions: These results show that treatment response and remission to mirtazapine were significantly associated with Alu insertion/deletion polymorphism of the tPA gene. This suggests that Alu insertion/deletion polymorphism affects the therapeutic action of mirtazapine in MDD, and may be a potential genetic marker for the prediction of therapeutic response to mirtazapine treatment in patients with MDD.
